Summary of Significant Accounting Policies - Segments (Details)	12 Months Ended
	Jun. 30, 2016 USD ($) item	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2015 USD ($)
Segment Information
Number of operating segments | item	1
Accounting Standards Update 2015-03
Recent Accounting Pronouncements
Deferred financing costs	$ 7,800,000
Accounting Standards Update 2015-17
Recent Accounting Pronouncements
Reduction in long-term assets and Liabilities, current				$ 843,000
Bayer | Revenues percentage | Customer concentration
Segment Information
Percentages of revenue recognized	17.00%
Lilly | Revenues percentage | Customer concentration
Segment Information
Percentages of revenue recognized	11.00%	21.00%	18.00%
Novartis | Revenues percentage | Customer concentration
Segment Information
Percentages of revenue recognized	1.00%	43.00%	38.00%
Roche | Revenues percentage | Customer concentration
Segment Information
Percentages of revenue recognized	43.00%	23.00%	34.00%
Takeda | Revenues percentage | Customer concentration
Segment Information
Percentages of revenue recognized	16.00%